Trial Profile

OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Adverse reactions
Acronyms Opti-HER; OptiHerHEART

09 Dec 2017 Results assessing the association of intrinsic subtype and immune genes with pathological complete response following neoadjuvant trastuzumab/pertuzumab-based chemotherapy (n=58) presented at the 40th Annual San Antonio Breast Cancer Symposium
21 Apr 2016 Status changed from active, no longer recruiting to completed.
23 Dec 2013 Planned end date changed from 1 May 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com